Cargando…

Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis

Melanoma is the most malignant form of skin cancer, which seriously threatens human life and health. Anti-PD-1 immunotherapy has shown clinical benefits in improving patients’ overall survival, but some melanoma patients failed to respond. Effective therapeutic biomarkers are vital to evaluate and o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xuanyi, Chai, Zixuan, Li, Yinghong, Long, Fei, Hao, Youjin, Pan, Guizhi, Liu, Mingwei, Li, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230292/ https://www.ncbi.nlm.nih.gov/pubmed/32316408 http://dx.doi.org/10.3390/genes11040435

Ejemplares similares

A Cancer Associated Fibroblasts-Related Six-Gene Panel for Anti-PD-1 Therapy in Melanoma Driven by Weighted Correlation Network Analysis and Supervised Machine Learning
por: Tian, Luyao, et al.
Publicado: (2022)

Consistent Biomarkers and Related Pathogenesis Underlying Asthma Revealed by Systems Biology Approach
por: Nie, Xiner, et al.
Publicado: (2019)

Identification of stage-associated exosome miRNAs in colorectal cancer by improved robust and corroborative approach embedded miRNA-target network
por: Long, Fei, et al.
Publicado: (2022)

A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity
por: Long, Fei, et al.
Publicado: (2023)

Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model
por: Contreras, Ana M., et al.
Publicado: (2016)

Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy
por: Wu, Xia, et al.
Publicado: (2021)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: Flaus, A., et al.
Publicado: (2021)

PD-L1 expression in pulmonary lymphoepithelioma-like carcinoma: is it a prognostic biomarker?
por: Li, Wen, et al.
Publicado: (2022)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma
por: Nie, Run-Cong, et al.
Publicado: (2019)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
por: Ascierto, Paolo A., et al.
Publicado: (2015)

Correlation of MET and PD-L1 Expression in Malignant Melanoma
por: Song, Kyu Young, et al.
Publicado: (2020)

Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
por: Shui, Irene M., et al.
Publicado: (2022)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
por: Gellrich, Frank Friedrich, et al.
Publicado: (2020)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

ITGAL as a prognostic biomarker correlated with immune infiltrates in melanoma
por: Deng, TengFei, et al.
Publicado: (2023)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
por: Hurkmans, Daan P, et al.
Publicado: (2020)

FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma
por: Wu, Shaobo, et al.
Publicado: (2022)

Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma
por: Serratì, Simona, et al.
Publicado: (2023)

The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
por: Zhong, Yanwen, et al.
Publicado: (2019)

Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
por: Zhao, Lingdi, et al.
Publicado: (2019)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Granulocyte Apheresis: Can It Be Associated with Anti PD-1 Therapy for Melanoma?
por: Sernicola, Alvise, et al.
Publicado: (2022)

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
por: Huuhtanen, Jani, et al.
Publicado: (2023)

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
por: Parakh, Sagun, et al.
Publicado: (2021)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
por: Kambayashi, Yumi, et al.
Publicado: (2019)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
por: Musaelyan, Aram A., et al.
Publicado: (2022)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8jvudtbiahdjlod1s0mj72vcpa